J&J Rybrevant Update Could Bode Positively For AstraZeneca’s Tagrisso
Executive Summary
A Phase III trial of Rybrevant with lazertinib versus Tagrisso in first line EGFR-positive NSCLC is continuing after an interim analysis, surprising some investors who thought it might be stopped early for efficacy.
You may also be interested in...
J&J’s Rybrevant Results Provide Encouragement After Interim Analysis Sparked Jitters
The company announced topline results for MARIPOSA in EGFR-mutant NSCLC, showing positive progression-free survival and a favorable trend on overall survival.
Daiichi Sankyo Comes Out Swinging At WCLC As ADCs Steal Show
The Japanese drug maker gave multiple presentations on AstraZeneca-partnered Enhertu and other deruxtecan-based ADCs. Plus Gilead presented data on Trodelvy, Amgen showed early frontline data for Lumakras, and J&J’s EGFR-directed bispecific Rybrevant showed a 50% ORR in heavily pretreated patients.
AstraZeneca’s Tagrisso Chemo Combo Impresses But Not A Gamechanger
The detailed results from FLAURA2 have provided a boost for AstraZeneca's Tagrisso franchise, although the combination of the drug plus chemotherapy is unlikely to challenge the convenience that the company's biggest earner already offers for most patients.